A phase I single dose study of CAM2029 for treatment of patients with acromegaly, neuroendocrine tumors (NETs).
Phase of Trial: Phase I
Latest Information Update: 06 May 2016
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly; Neuroendocrine tumours
- Focus Adverse reactions
- 06 May 2016 New trial record